Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients
NCT ID: NCT05728528
Last Updated: 2023-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
13 participants
INTERVENTIONAL
2022-07-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Influence of "Karate" on Bleeding in Hemophilic Patients.
NCT00281333
Association Between Individual Clotting Factor Level Monitoring and the Risk of Bleeding Whilst Physical Active Conditions
NCT04845555
Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement
NCT03182751
Topical Tranexamic Acid (TXA) in Hip Fractures
NCT02993341
Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin/Hematocrit
NCT05357079
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities
PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities
combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
PK-guided EHL FVIII concentrates prophylaxis alone
PK-guided EHL FVIII concentrates prophylaxis alone
pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Darintr Sosothikul
Associate Professor, Head of Integrative and Innovative Hematology/Oncology Research Unit at Faculty of Medicine, Chulalongkorn University.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King Chulalongkorn Memorial Hospital
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Srichumpuang C, Rakmanotham A, Moonla C, Sosothikul D. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis. Orphanet J Rare Dis. 2024 Mar 26;19(1):135. doi: 10.1186/s13023-024-03092-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
996/2565
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.